SLC5A2 and acute kidney injury: Recent large‐scale clinical trials and meta‐analysis have shown that SGLT2 inhibitors may even protect type 2 diabetic patients from AKI, although an increase in AKI related to the diuretic property and resulting volume depletion have been a concern (Donnan et al., 2019; Gilbert & Thorpe, 2019).